Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

Roberts, Megan C.; Miller, Dave P.; Shak, Steven; Petkov, Valentina I.

doi:10.1007/s10549-017-4162-3

Cited by 85 publications

(92 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecular assays (eg, a loss of heterozygosity) are more reliable approaches for showing clonal relationships between original tumors and ipsilateral IBCs and for distinguishing genetically related recurrences from genetically distinct new primaries. Using commonly used definitions of intermediate (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) and high recurrence risks (≥31) generated a similar result. The 21-gene recurrence score is an assay based on reverse transcription-polymerase chain reaction that is currently applied to early-stage, ER+ IBC to assess the prognosis and the likely benefit from chemotherapy in addition to endocrine therapy.…”

Section: Discussionmentioning

confidence: 62%

Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ

Liu

West

Weber

et al. 2019

Cancer

View full text Add to dashboard Cite

Background General populations of black women have a higher risk of developing breast cancer negative for both estrogen receptor (ER) and progesterone receptor (PR) in comparison with white counterparts. Racial differences remain unknown in the risk of developing aggressive invasive breast cancer (IBC) that is characterized by negativity for both ER and PR (ER–PR–) or higher 21‐gene recurrence scores after ductal carcinoma in situ (DCIS). Methods This study identified 163,892 women (10.5% black, 9.8% Asian, and 8.6% Hispanic) with incident DCIS between 1990 and 2015 from the Surveillance, Epidemiology, and End Results data sets. Cox proportional hazards regression was used to estimate hazards ratios (HRs) of subsequent IBC classified by the hormone receptor status and 21‐gene recurrence scores. Results During a median follow‐up of 90 months, 8333 women developed IBC. In comparison with white women, the adjusted HR of subsequent ER–PR– breast cancer was 1.86 (95% confidence interval [CI], 1.57‐2.20) for black women (absolute 10‐year difference, 2.2%) and 1.40 (95% CI, 1.14‐1.71) for Asian women (absolute 10‐year difference, 0.4%); this was stronger than the associations for ER+ and/or PR+ subtypes (Pheterogeneity = .0004). The 21‐gene recurrence scores of subsequent early‐stage, ER+ IBCs varied by race/ethnicity (Pheterogeneity = .057); black women were more likely than white women to have a recurrence score of 26 or higher (HR, 1.38; 95% CI, 1.00‐1.92). No significant difference was observed in the risks of subsequent IBC subtypes for Hispanic women. Conclusions Black and Asian women with DCIS had higher risks of developing biologically aggressive IBC than white counterparts. This should be considered in treatment decisions for black and Asian patients with DCIS.

show abstract

Section: Discussionmentioning

confidence: 62%

Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ

Liu

West

Weber

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…The identification of patients with high clinical risk and low genomic score with at least a 92.5% chance of being free of distant metastasis without chemotherapy at 5 years was demonstrated using the Mammaprint assay in the MINDACT trial . Prospective outcomes in >60,000 patients (including both clinical and epidemiological data) treated based on 21‐gene assay results have shown that patients within the low RS group (RS < 18) have excellent outcomes without chemotherapy . The prognostic power of the RS was validated in an endocrine‐treated NSABP B14 cohort, in the Kaiser Permanante, JBCRG, SWOG 8814 and in the transATAC studies .…”

Section: Introductionmentioning

confidence: 99%

Summary of head‐to‐head comparisons of patient risk classifications by the 21‐gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer

Varga

Sinn

Seidman

2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21‐gene assay results have shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score (RS) results (RS < 18). Because of its extensive validation and wide clinical use, the RS assay is a common comparator in head‐to‐head studies with other assays. Published/presented studies of the RS assay performed on the same tumor samples with Breast Cancer Index (BCI), EndoPredict (EP) or EP+ clinical features (EPclin), MammaPrint (MMP) and/or Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively.

show abstract

“…It was seen that CT was beneficial in distinguishing nodepositive patients who would benefit from CT (Predictor of likelihood of chemotherapy benefit in ER+ Node positive disease). Its prospective validation in the node-positive patients was demonstrated in the West German Study Group Plan B Randomized Phase-3 study, the Clalit Registry study conducted in Israel and the SEER real-life observational study (31)(32)(33). In all these studies, the 5-year survival rate of patients in the low risk group is >95%.…”

Section: -Gene Recurrence Score Assay (Oncotype Dx) (Table 3)mentioning

confidence: 98%

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Güler

2017

Eur J Breast Health

View full text Add to dashboard Cite

Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

Cited by 85 publications

References 17 publications

Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ

Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ

Summary of head‐to‐head comparisons of patient risk classifications by the 21‐gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Contact Info

Product

Resources

About